UCB, Inc. et al. v. Accord Healthcare, Inc., et al., C.A. No. 13-1206-LPS, August 12, 2016 (unsealed on August 15, 2016).
Stark, C. J. The court rules the patents-in-suit are not invalid. Defendants had stipulated to infringement of the asserted claims. Parties are to submit a proposed order final judgment in favor of plaintiff and against defendants.
The disputed product is an anti-epilectic drug with the active ingredient lacosamide. Defendants failed to prove that the disputed claims are invalid for obviousness-type double patenting, obviousness, anticipation, indefiniteness, or improper reissue.